<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03553238</url>
  </required_header>
  <id_info>
    <org_study_id>PDT-ETP-ALL</org_study_id>
    <nct_id>NCT03553238</nct_id>
  </id_info>
  <brief_title>Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL</brief_title>
  <official_title>An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Target Total Therapy for Adult Early T-cell Progenitor Acute Lymphoblastic Leukemia/Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ETP-ALL is a recently recognized high-risk subgroup and the optimal therapeutic approaches
      are poorly characterized. Based on the pediatric-inspired, PEG-L-asparaginase-intensified and
      MRD-directed PDT-ALL-2016 protocol, this open-label, one-arm, multi-site trial is aimed to
      evaluate the safety and effect of a novel oral histone deacetylase inhibitor chidamide for
      adult ETP-ALL/LBL in CHINA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Early T-cell precursor (ETP) lymphoblastic leukemia (ETP-ALL) is a neoplasm composed of cells
      committed to the T-cell lineage but with an unique immunophenotype indicating only limited
      early T differentiation. In the highly orchestrated development of T cell fate specification
      under physiological condition, the most immature early thymic progenitors (ETPs) retain
      multilineage potentials. ETP-ALL blasts have a characteristic immunophenotype, with
      reduced/absent expression of T-lymphoid markers CD1a, CD5, CD8; and positivity for at least
      one HSC and/or myeloid antigen CD34, CD117, HLA-DR, CD13, CD33, CD11b, CD65. Recent study
      shed light on the genetic landscape of adult ETP-ALL, which revealed that more than 40% adult
      ETP-ALL harbored histone modification mutations. Chidamide is a novel oral HDACi with
      promising activity in non-Hodgkin lymphoma (NHL). Based on the pediatric-inspired,
      PEG-L-asparaginase-intensified and MRD-directed PDT-ALL-2016 protocol, this open-label,
      one-arm, multi-site trial is aimed to evaluate the safety and effect of a novel oral histone
      deacetylase inhibitor chidamide for adult ETP-ALL/LBL. HDACi chidamide at a dose of 10mg/day
      will be added to ETP-ALL group from induction therapy to consolidation therapy (total courses
      of chidamide treatment: 5 courses for allo-HSCT after Consolidation Module-3; 12 courses for
      patients non-allo-HSCT after Consolidation Module 1-9). Primary study endpoint of PDT-ETP-ALL
      is event-free survival of ETP-ALL group and secondary study endpoints are complete remission
      and MRD after induction, adverse event and overall survival of ETP-ALL group.

      Pretreatment: Dexamethasone, -3 to 0d;

      Induction:VCR: 1, 8, 15, 22; IDA: 1, 8; CTX: 1g/m2, 1, 8; PEG-asp: 2000-2500IU/m2, 1, 15;
      Dex: 1-24, chidamide: 10mg/d, po, qd.

      MRD: d14, 24, 45, and pre-allo-HSCT.

      VLCAM (MRD1/d14&gt;1%): CTX, d25; AraC 2g/m2, q12h, d25, 26; 6-MP: 25-31, PEG-asp: 26;
      chidamide: 10mg/d, po, qd.

      Consolidation Module:

      CM-1: AraC 3g/m2, q12h, 1-2, Dex: 10mg/m2, 1-2, PEG-asp: 2, 6-MP: 1-7. IT: d1, chidamide:
      10mg/d, po, qd.

      CM-2: MTX 5g/m2, 1, Dex: 10mg/m2, 1-2, PEG-asp: 2; 6-MP: 1-7; IT: d1; chidamide: 10mg/d, po,
      qd.

      CM-3: CTX 0.5g/m2, 1-3, PEG-asp: 2, Doxorubicin: 40mg/m2, 4, 6-MP: 1-7, IT: d1;chidamide:
      10mg/d, po, qd.

      Allo-HSCT: after CM-3 when donors available. Non-HSCT: finish CM 4-9 and POMP maintenance.

      CM 4-6: repeat CM 1-3. Re-Induction: after CM-6. CM 7-9: repeat CM1-3.

      Maintenance: CPOMP-chidamide 10mg/d, po, qd; Pred for 12 months; VCR for 12 months; MTX for
      24 months; 6-MP for 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2016</start_date>
  <completion_date type="Anticipated">August 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minimum residual disease after induction</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR after Induction Therapy</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death in induction</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Leukemia, Acute</condition>
  <condition>Leukemia, T Cell</condition>
  <condition>Leukemia, Lymphoblastic</condition>
  <arm_group>
    <arm_group_label>ETP-ALL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chidamide at a dose of 10mg/day will be added to PDT-ETP-ALL protocol. The intervention of PDT-ETP-ALL consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, Karyotyping ，FISH, NGS, Flow-MRD, PET-CT scan), induction regimen (chidamide, dexamethasone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, prednisone, cytarabine, methotrexate, cyclophosphamide, etoposide, adriamycin, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen (chidamide, prednisone, vincristine, methotrexate, 6-mercaptopurine), intrathecal injection chemotherapy, radiation therapy (for mediastinum- and/or central nervous system-involved lymphoma/leukemia) and allogeneic hematopoietic stem cell transplantation for patients with donor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chidamide</intervention_name>
    <description>Chidamide will be administrated at a dose of 10mg/day in PDT-ETP-ALL protocol.</description>
    <arm_group_label>ETP-ALL</arm_group_label>
    <other_name>HDACi chidamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone will be added in Pre-phase Regimen, Induction-Regimen, Consolidation-Module of PDT-ETP-ALL protocol.</description>
    <arm_group_label>ETP-ALL</arm_group_label>
    <other_name>DXM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine</intervention_name>
    <description>Vincristine will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.</description>
    <arm_group_label>ETP-ALL</arm_group_label>
    <other_name>VCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>CTX will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.</description>
    <arm_group_label>ETP-ALL</arm_group_label>
    <other_name>CTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <description>IDA will be added to Induction-Regimen and Consolidation-Module of PDT-ETP-ALL protocol.</description>
    <arm_group_label>ETP-ALL</arm_group_label>
    <other_name>IDA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegaspargase</intervention_name>
    <description>PEG-ASP will be added to Induction-Regimen and Consolidation-Module of PDT-ETP-ALL protocol.</description>
    <arm_group_label>ETP-ALL</arm_group_label>
    <other_name>PEG-ASP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adriamycin</intervention_name>
    <description>Adriamycin will be added to Consolidation-Module of PDT-ETP-ALL protocol.</description>
    <arm_group_label>ETP-ALL</arm_group_label>
    <other_name>ADR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate will be added to consolidation module of PDT-ETP-ALL protocol.</description>
    <arm_group_label>ETP-ALL</arm_group_label>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6-Mercaptopurine</intervention_name>
    <description>Mercaptopurine will be added to Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.</description>
    <arm_group_label>ETP-ALL</arm_group_label>
    <other_name>6-MP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>VP-16 will be added to Consolidation-Module of PDT-ETP-ALL protocol.</description>
    <arm_group_label>ETP-ALL</arm_group_label>
    <other_name>VP-16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>AraC will be added to Consolidation-Module of PDT-ETP-ALL protocol.</description>
    <arm_group_label>ETP-ALL</arm_group_label>
    <other_name>AraC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone marrow aspiration</intervention_name>
    <description>Bone marrow aspiration and additional tests will be performed in all module of PDT-ETP-ALL protocol.</description>
    <arm_group_label>ETP-ALL</arm_group_label>
    <other_name>BM test</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intrathecal injection</intervention_name>
    <description>Intrathecal injection chemotherapy will be performed in PDT-ETP-ALL protocol.</description>
    <arm_group_label>ETP-ALL</arm_group_label>
    <other_name>IT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>Radiation therapy will be performed for mediastinum and/or central nervous system leukemia in PDT-ETP-ALL protocol.</description>
    <arm_group_label>ETP-ALL</arm_group_label>
    <other_name>RT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>NGS</intervention_name>
    <description>Next-Generation-Sequencing (NGS) will be performed in PDT-ETP-ALL protocol.</description>
    <arm_group_label>ETP-ALL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Allo-HSCT will be performed for patients with available donor in PDT-ETP-ALL protocol.</description>
    <arm_group_label>ETP-ALL</arm_group_label>
    <other_name>allo-HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Flow-MRD</intervention_name>
    <description>Flow-MRD will be added to PDT-ETP-ALL for bone marrow and cerebrospinal fluid samples.</description>
    <arm_group_label>ETP-ALL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>FISH</intervention_name>
    <description>FISH will be performed in PDT-ETP-ALL for bone marrow samples.</description>
    <arm_group_label>ETP-ALL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Flow immunophenotyping</intervention_name>
    <description>Flow immunophenotyping will be performed in PDT-ETP-ALL protocol.</description>
    <arm_group_label>ETP-ALL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Karyotyping</intervention_name>
    <description>Karyotyping will be performed in PDT-ETP-ALL protocol.</description>
    <arm_group_label>ETP-ALL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  14-55 years old;

          -  ETP-ALL newly diagnosed;

          -  signed written informed consent

        Exclusion Criteria:

          -  Pregnant women;

          -  History of pancreatitis;

          -  History of diabetes;

          -  History of active peptic ulcer disease in the past 6 months;

          -  History of arteriovenous thrombosis in the past 6 months;

          -  Severe active infection;

          -  Allergic to any drugs in PDT-ETP-ALL.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongsheng Zhou, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Nanfang Hospital, Southern Medical University, CHINA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongsheng Zhou, MD, Ph.D</last_name>
    <phone>+862062787349</phone>
    <email>zhs1@i.smu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongsheng Zhou, MD, PhD</last_name>
      <phone>+862062787349</phone>
      <email>zhs1@i.smu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Koch U, Radtke F. Mechanisms of T cell development and transformation. Annu Rev Cell Dev Biol. 2011;27:539-62. doi: 10.1146/annurev-cellbio-092910-154008. Epub 2011 Jul 5. Review.</citation>
    <PMID>21740230</PMID>
  </reference>
  <reference>
    <citation>Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11. Review.</citation>
    <PMID>27069254</PMID>
  </reference>
  <reference>
    <citation>Bond J, Graux C, Lhermitte L, Lara D, Cluzeau T, Leguay T, Cieslak A, Trinquand A, Pastoret C, Belhocine M, Spicuglia S, Lheritier V, Leprêtre S, Thomas X, Huguet F, Ifrah N, Dombret H, Macintyre E, Boissel N, Asnafi V. Early Response-Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study. J Clin Oncol. 2017 Aug 10;35(23):2683-2691. doi: 10.1200/JCO.2016.71.8585. Epub 2017 Jun 12.</citation>
    <PMID>28605290</PMID>
  </reference>
  <reference>
    <citation>Yu S, Zhou X, Steinke FC, Liu C, Chen SC, Zagorodna O, Jing X, Yokota Y, Meyerholz DK, Mullighan CG, Knudson CM, Zhao DM, Xue HH. The TCF-1 and LEF-1 transcription factors have cooperative and opposing roles in T cell development and malignancy. Immunity. 2012 Nov 16;37(5):813-26. doi: 10.1016/j.immuni.2012.08.009. Epub 2012 Oct 25. Erratum in: Immunity. 2014 Jan 16;40(1):166.</citation>
    <PMID>23103132</PMID>
  </reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>April 21, 2018</study_first_submitted>
  <study_first_submitted_qc>June 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2018</study_first_posted>
  <last_update_submitted>June 11, 2018</last_update_submitted>
  <last_update_submitted_qc>June 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Qifa Liu</investigator_full_name>
    <investigator_title>M.D., Professor</investigator_title>
  </responsible_party>
  <keyword>Early T-cell Precursor</keyword>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>Histone Deacetylase Inhibitor</keyword>
  <keyword>Chidamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Mercaptopurine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

